Nanjing Drum Tower Hospital Licenses Two Patents for Up to RMB 20 Million; Innovent Biologics Signs Commercialization Deal with Aosaikang Pharma

20 Million! Nanjing Drum Tower Hospital Transfers Two Patents

Nanjing Gulou Hospital announced a technology transaction. Reportedly, the hospital plans to exclusively license two core medical technologies to Jiangsu Yahuan Software Co., Ltd. at a capped transaction price of 20 million yuan (including an upfront fee of 200,000 yuan, milestone payments of 2.8 million yuan, and sales royalties capped at 17 million yuan). The technologies are the invention patent "A Wearable Device with Olfactory Detection Function" (Patent No.: ZL 202311025050.0) and the software copyright "Type 2 Diabetes Mild Cognitive Impairment Risk Assessment Software" (Registration No.: 2022SR0519228). (Source: Arterial Network)

Innovent Bio Rises Over 3%, Signs Cooperation Agreement with AOSAIKANG PHARM

Recently, Innovent Bio and AOSAIKANG PHARM (002755) signed a cooperation agreement. The two parties will enter into an exclusive commercialization collaboration for the third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) targeted drug "Liotinib Tablets" (brand name: Aoyixin). It is reported that the National Medical Products Administration is currently reviewing and approving the new drug marketing applications for two indications of Liotinib Tablets. TF Securities (601162) pointed out that in the first half of 2024, Innovent Bio's total revenue was 3.95 billion yuan, representing a year-on-year increase of 46.3%; product revenue was 3.81 billion yuan, marking a year-on-year growth of 55.1%. The company’s products have maintained high year-on-year growth for multiple consecutive quarters. Considering the continued sales growth of its marketed products and multiple R&D pipelines approaching the harvest stage, the brokerage firm raised the company's revenue forecasts for 2024 and 2025 from 7.225 billion yuan and 9.193 billion yuan to 7.97 billion yuan and 10.235 billion yuan, respectively, and projected that revenue in 2026 would reach 13.143 billion yuan. (Source: Zhitong Finance)

Expected to Increase Revenue by 500 Million Yuan! Abbott's Laboratory Automation Products Achieve Localized Production in China

On October 9, Abbott announced the official launch of its domestically produced immune module Alinity i and automated assembly line GLP, marking a new chapter in the localized production of these two intelligent solutions at Abbott's diagnostic facility in Hangzhou. According to a report by the Qiantang New District, this project is the first locally implemented imported medical device localization project in Hangzhou City. It is expected to commence operations in 2025, at which time it will generate an additional annual industrial output value of 300 million yuan and is anticipated to drive annual revenue growth of 500 million yuan. (Source: Arterial Network)

AOSAIKANG PHARM Invests 220 Million Yuan, Aiming at Biologic Innovation Drugs

On October 9, 2024, AOSAIKANG PHARM announced that it had invested RMB 220 million in cash into AskGene Limited through its wholly-owned subsidiary, Sea Glory Group Limited. The funds from this capital increase will mainly be used for AskGene's daily operations, research and development, and other aspects. (Source: Arterial Network)

iRegene Completes Over 100 Million Yuan in Series B Financing

Recently, Wuhan iRegene Pharmaceutical Technology Co., Ltd. ("iRegene" or "the Company"), which is committed to becoming a globally leading universal chemically induced cell therapy drug enterprise, announced the completion of an over RMB 100 million Series B financing round. This round was jointly led by Ceyuan Capital and Guosheng Capital, with participation from well-known industry investment institutions and Wuhan Optics Valley Industrial Investment. (Source: Arterial Network)

Quark Pharmaceuticals Completes Series A Financing

Recently, Quark Medicine Successfully Completed Series A Financing, Securing Tens of Millions of RMB in Funding Led by TaiKun Fund, with Mint Venture Capital and Guoshun Jianheng Fund as Follow-up Investors. Against the backdrop of a global economic downturn and slowing pharmaceutical investments, Quark Medicine has defied the trend, further demonstrating its comprehensive strength in clinical research services. (Source: Arterial Network)

Chengqi Zhizao Raises Tens of Millions in Angel Round Financing

On October 10, 2024, Chengqi Intelligent Manufacturing (Beijing) Technology Co., Ltd. (hereinafter referred to as "Chengqi Intelligent Manufacturing") officially announced the completion of an angel round of financing worth tens of millions of yuan. This round of financing was jointly invested by Huatai Jinsirui, Shuimu Ventures, and Daoyuan Capital, with Index Capital serving as the exclusive financial advisor. (Source: Arterial Network)

91360 Pathology AI Company Successfully Completes New Round of Financing

Recently, 91360, a leading company in China's pathology AI field, announced the successful completion of a new round of financing. This round was led by Ivy Capital, with follow-up investment from Hangzhou Gongshu District State-owned Investment. The funds will support 91360 in promoting and implementing its comprehensive solution for AI-assisted diagnosis in cervical cytology, as well as advancing digital pathology solutions, teleconsultation platform services, and innovative business initiatives. (Source: Arterial Network)

Sales of chemical oral liquid preparations at public medical institutions in China exceeded 23 billion yuan in 2023

Recently, Six Oral Liquid Preparations Approved for Marketing on the Same Day. Data from Menet shows that in 2023, the sales of chemical oral liquid preparations in China's public medical institutions exceeded 23 billion yuan, with Nutricia and Fresenius Kabi leading the market. Among the top 20 brands, two blockbuster products each exceeding 1 billion yuan are at the forefront, while an antitussive and expectorant drug surged by 167%. Eight drugs in the oral liquid category have been included in national procurement, with 19 drugs preparing for the tenth round of procurement. Multiple products from companies such as Betta, Yangtze River Pharma, Renhe Yikang, Chengji Pharma, and Hengrui are on the list. (Source: Menet)

"2024 Edition of the Antibacterial Drug Classification Management Catalog" Released

In recent years, the standardized clinical use of antimicrobial drugs has drawn significant attention. From 2024 to date, regions such as Jiangsu, Beijing-Tianjin-Hebei, Guangdong, Shanghai, Hainan, and Tibet have successively updated the "2024 Edition of the Antimicrobial Drug Classification Management Catalog," involving 201, 122, 180, 105, 129, and 93 varieties respectively. Antimicrobial drugs are a major category of systemic anti-infective drugs; in Q1 2024, the sales scale of systemic anti-infective drugs in key city public hospital terminals in China exceeded 7.5 billion yuan. Among the top 20 brands, domestic brands such as Dongyang Light Pharma and Hansoh achieved double-digit growth. The launch of nine Class 1 new drugs is highly anticipated, with domestic companies like Zhongsheng and Qingfeng poised for action. (Source: Menet)